Ovalicin
CAS 19683-98-8
Ovalicin (CAS 19683-98-8) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 5833.466666666667 nM | 3 | - |
| - | GI50 | 4100 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Ovalicin used for in pharmaceutical contexts?
Ovalicin (CAS 19683-98-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Ovalicin?
No adverse-event association or SIDER side-effect rows are rendered for Ovalicin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Ovalicin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for OVALICIN with EU status "permitted".
What clinical phase is Ovalicin in?
No phase 1-4 clinical development badge is rendered for Ovalicin because the matched compound identifier rows do not contain a max-phase value.